NEW YORK, Jan 16 - Quantum Dot said Tuesday that GlaxoSmithKline has agreed to help in evaluating the company’s SNP detection assays. Financial terms of the deal were not disclosed. Andy Watson, vice president of systems at QDC, said the evaluation could potentially lead to a licensing agreement. "They’ll be using their expertise to evaluate the data we generate and to see how applicable it is to their needs," said Watson.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.